9,10-dioxa-syn-(methylthiomethyl,methyl)(methyl,methyl)bimane | 76421-82-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡唑类
• 英文名称: 9,10-dioxa-syn-(methylthiomethyl,methyl)(methyl,methyl)bimane
• 英文别名: 1,2,6-Trimethyl-7-(methylsulfanylmethyl)pyrazolo[1,2-a]pyrazole-3,5-dione
• CAS: 76421-82-4
• 化学式: C₁₁H₁₄N₂O₂S
• 分子量: 238.31
• InChiKey: RFINUPUQWVIVIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  65.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,5-双溴甲基-2,6-二甲基吡唑并[1,2-a]吡唑-1,7-二酮 、 sodium thiomethoxide 以 乙醇 为溶剂， 反应 3.0h， 以58%的产率得到9,10-dioxa-syn-(methylthiomethyl,methyl)bimane
  参考文献：
  名称：

  Bimanes. 6. Reactive halogen derivatives of syn- and anti-1,5-diazabicyclo[3.3.0]octadienediones (9,10-dioxabimanes)

  摘要：

  DOI：

  10.1021/jo00321a029

文献信息

• 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
  申请人：Gamber Gabriel G.

  公开号：US20090306373A1

  公开（公告）日：2009-12-10

  This invention relates generally to compounds and pharmaceutical compositions for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions.

  本发明涉及一般用于治疗肌球蛋白重链（MyHC）介导的疾病，特别是心血管疾病的化合物和制药组合物。
• Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds
  申请人：Gamber Gabriel G.

  公开号：US20110105496A1

  公开（公告）日：2011-05-05

  This invention relates generally to methods for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions.

  本发明涉及治疗肌球蛋白重链（MyHC）介导的疾病的方法，特别是心血管疾病的方法。
• METHOD AND KIT FOR ASSESSING VIABLE CELLS
  申请人：ChemoMetec A/S

  公开号：US20160131658A1

  公开（公告）日：2016-05-12

  The present invention provides simple, rapid methods and procedures for analyzing cells, hereunder quantitative and qualitative assessment of cells, such as viability. The present invention relates to the use of various optionally substituted reporter compounds particularly detectable upon their reaction with thiol-containing species present in higher concentrations in intact (e.g., living) cells than in non-intact (e.g., dead, stressed and apoptotic) cells. The present invention also relates to the use of various optionally substituted reporter compounds particularly detectable upon their reaction with species present in intact and/or non-intact cells. Moreover, the present invention relates to the use of measuring techniques and/or instruments coupled with the use of various optionally substituted reporter compounds. The invention further relates to compositions used in methods for analyzing cells, such as a composition comprising N-(7-dimethylamino-4-methyl-3-coumarinyl)-maleimide (DACM).
• US9128097B2
  申请人：——

  公开号：US9128097B2

  公开（公告）日：2015-09-08
• [EN] USE OF 4, 7-DIHYDROTHIENO [2, 3-B] PYRIDINE COMPOUNDS IN THE TREATMENT OF CARDIOVASCULAR DISEASES<br/>[FR] UTILISATION DE COMPOSES DE 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES
  申请人：GILEAD COLORADO INC

  公开号：WO2007073555A1

  公开（公告）日：2007-06-28

  [EN] This invention relates generally to methods for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions.
  [FR] Cette invention concerne de manière générale des procédés pour le traitement d'états induits par la chaîne lourde de myosine (MyHC), notamment de maladies cardiovasculaires.